Physician profile
Deetta M Gray
NPI 1790825966
$9,161.98
in general payments reported to CMS, 2019-2025
27 companies · $1,007 in 2025
The $1,007 reported for 2025 was more than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,456 · 2020: $738 · 2021: $1,509 · 2022: $1,618 · 2023: $1,475 · 2024: $1,358 · 2025: $1,007.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,761 · Education: $80.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,760.78 |
| Education | $80.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,299.13 | 2019-2025 | |
| Galderma Laboratories, L.P. | $1,110.56 | 2019-2025 | Nemluvio, Aklief |
| E.R. Squibb & Sons, L.L.C. | $960.47 | 2022-2025 | Sotyktu |
| Merz North America, INC. | $948.55 | 2019-2023 | Xeomin |
| Incyte Corporation | $498.91 | 2021-2025 | Opzelura |
| Leo Pharma INC. | $437.96 | 2019-2025 | Adbry, Anzupgo |
| Ucb, INC. | $412.10 | 2020-2024 | Bimzelx |
| Genzyme Corporation | $386.70 | 2019-2025 | |
| Amgen INC. | $383.60 | 2020-2024 | Otezla |
| Janssen Biotech, INC. | $341.04 | 2020-2025 | Tremfya |
| Pfizer INC. | $331.32 | 2019-2025 | |
| Allergan, INC. | $301.03 | 2019-2022 | |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $264.61 | 2019-2025 | Cabtreo, Jublia |
| Regeneron Healthcare Solutions, INC. | $254.17 | 2019-2025 | Dupixent |
| Novartis Pharmaceuticals Corporation | $230.03 | 2019-2025 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Dermavant Sciences, INC. | $200.86 | 2023-2024 | Vtama |
| Sun Pharmaceutical Industries INC. | $162.05 | 2024-2025 | |
| Lilly USA, LLC | $142.45 | 2019-2024 | Taltz, Ebglyss, Olumiant |
| Almirall LLC | $136.14 | 2019-2022 | |
| Arcutis Biotherapeutics, INC. | $91.33 | 2023-2024 | Zoryve |
| Dermira, INC. | $88.60 | 2019-2021 | |
| Celgene Corporation | $42.57 | 2019 | |
| Organon LLC | $41.24 | 2025 | Vtama |
| Botanix Sb INC | $26.28 | 2025 | Sofdra |
| Vyne Pharmaceuticals INC. | $25.32 | 2021 | |
| Sandoz INC. | $24.22 | 2019 | |
| Mayne Pharma Commercial LLC | $20.74 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Deetta Gray listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.